Table 6.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1992 to 2001

Recipients with Pancreas Transplant Alone (PTA) Transplants

		Year of Transplant
		1992	1993	1994	1995	1996	1997	1998	1999	2000	2001
Transplants		35	52	39	41	53	78	88	136	135	163
Tx with Antirejection Treatments		19	16	17	24	22	21	21	32	28	21
Antibodies	Category Usage	100.0%	75.0%	70.6%	54.2%	54.5%	66.7%	52.4%	84.4%	89.3%	61.9%
	ALG	63.2%	37.5%	17.6%	4.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG	0.0%	0.0%	5.9%	4.2%	36.4%	19.0%	9.5%	0.0%	0.0%	4.8%
	NRATG/NRATS	0.0%	0.0%	0.0%	0.0%	4.5%	0.0%	0.0%	0.0%	0.0%	0.0%
	OKT3	68.4%	56.3%	64.7%	50.0%	40.9%	57.1%	47.6%	68.8%	53.6%	28.6%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	9.5%	37.5%	53.6%	38.1%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	12.5%	3.6%	4.8%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.1%	3.6%	4.8%
Corticosteroids	Category Usage	15.8%	25.0%	52.9%	50.0%	90.9%	66.7%	71.4%	75.0%	78.6%	90.5%
	Steroids	15.8%	25.0%	52.9%	50.0%	90.9%	66.7%	71.4%	75.0%	78.6%	90.5%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.